Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: An analysis of GDC-0973, a MEK inhibitor

Clinical Cancer Research

Volumn 18, Issue 11, 2012, Pages 3090-3099

  Wong, Harvey ^a   Vernillet, Laurent ^a   Peterson, Amy ^a   Ware, Joseph A ^a   Lee, Lillian ^b   Martini, Jean Francois ^b   Yu, Peiwen ^b   Li, Congfen ^b   Del Rosario, Geoffrey ^b   Choo, Edna F ^a   Hoeflich, Klaus P ^a   Shi, Yongchang ^b   Aftab, Blake T ^b   Aoyama, Ron ^b   Lam, Sanh Tan ^b   Belvin, Marcia ^a   Prescott, John ^a  

^a GENENTECH INC   (United States)

^b EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[3,4 DIFLUORO 2 (2 FLUORO 4 IODOPHENYLAMINO)PHENYL][3 HYDROXY 3 (PIPERIDIN 2 YL)AZETIDIN 1 YL]METHANONE; GDC 0973; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; XL 518;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MELANOMA; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AZETIDINES; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, BIOLOGICAL; PIPERIDINES; PROTEIN KINASE INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861771818     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0445     Document Type: Article

References (36)

1. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47. (Pubitemid 39626217)
2. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-84.
3. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/ MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14: 342-6. (Pubitemid 351226098)
4. Chapman MS, Miner JN. Novel mitogen-activated protein kinase kinase inhibitors. Expert Opin Investig Drugs 2011;20:209-20
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54. (Pubitemid 34716871)
6. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002;62:6451-5 (Pubitemid 35364105)
7. Li N, Batt D, Warmuth M. B-Raf kinase inhibitors for cancer treatment. Curr Opin Investig Drugs 2007;8:452-6. (Pubitemid 46868066)
8. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40. (Pubitemid 36627818)
9. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAFmutation predicts sensitivity to MEK inhibition. Nature 2006;439: 358-62 (Pubitemid 43128863)
10. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010;16:1924-37.
11. Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010;16:1613-1623.
12. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
13. Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2011;2:336-46
14. Poulikakos PI, Solit DB. Resistance to MEK inhibitors: should we target upstream? Sci Signal 2011;4:pe16.
15. Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 2012;72:210-9.
16. Rosen L, LoRusso P, Ma WW, Goldman J, Weise A, Colevas A, et al. A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; 2011.Abstract nr 4716.
17. Bauer RJ, Guzy S. Monte Carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic (PK/PD) data. In:D'Argenio DZ, editor. Advanced methods of pharmacokinetic and pharmacodynamic system analysis. Boston, MA: Kluwer; 2004. p. 135-63.
18. D'Argenio DZ, Schumitzky A. ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software. Los Angeles, CA: Biomedical Simulations Resource; 1997.
19. Tan W, DePrimo SE, Krishnamurthi SS, Rinehart JJ, Nabell LM, Nickens D, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) results of a phase I study of PD-0325901, a second generation oral MEK inhibitor, in patients with advanced cancer. Mol Cancer Ther 2007; 6:3648s. Abstract nr B109.
20. LoRusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281-93. (Pubitemid 46206982)
21. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67. (Pubitemid 38410730)
22. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 2003;31:510-8. (Pubitemid 36444157)
23. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, et al. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 2008;36:1267-74 (Pubitemid 351929310)
24. Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26: 1596-602.
25. Lin JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995;23:1008-21
26. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009;106:20411-6.
27. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010;3:ra84.
28. Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010; 102:1724-30.
29. Huang CY, Ferrell JE Jr. Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 1996;93:10078-83.
30. Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, et al. Pharmacodynamics of 2-{4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden- 5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: relationships between systemic concentrations, pMEK1 inhibition, and efficacy. J Pharmacol Exp Ther 2009;329:360-7.
31. Liu L, Di Paolo J, Barbosa J, Rong H, Reif K, Wong H. Anti-arthritis effect of a novel Bruton's tyrosine kinase inhibitor in rat collageninduced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol and Exp Ther 2011;338: 154-63.
32. Wong H, Alicke B, West K, Pacheco P, La H, Januario T, et al. Relationship between hedgehog pathway modulation and anti-tumor effect in preclinical models of mutational and ligand-driven tumors: a pharmacokinetic-pharmacodynamic analysis using vismodegib. Clin Canc Res 2011;17:4682-92.
33. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 2010;467:596-9.
34. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004;40:827-36. (Pubitemid 38519761)
35. Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther 2006;5:2435-43. (Pubitemid 44650906)
36. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res 2003;20:1337-50. (Pubitemid 37164040)